← Leaderboards
Mohan Rao Kaadige
Stingray Therapeutics, Inc.
$1,485,105
Attributed
$3,457,194
Total exposure
1
Grants
1
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $1.5M · FY2022–25$2M$1.5M$1M$500K$0
'22
'23
'24
'25
Funding mix
By agency
NIH$3,457,194 · 1
By mechanism
R44$3,457,194 · 1
Top collaborators
- Sunil Sharma3 shared
- Monil Shah1 shared
Others in their field
Other Rising Stars on “Innate Immune System”
- Gregory Sorenson · University Of Maryland Baltimore County$9,161,697
- Lisa Wagar · University Of California-Irvine$5,972,985
- Philip Felgner · University Of California-Irvine$5,352,389
- Mohsan Saeed · Boston University Medical Campus$3,674,026
- Yanling Wang · Rush University Medical Center$2,986,919
- Tyson Heilherker · Boston Children'S Hospital$2,818,454
Research focus
Innate Immune SystemProgrammed Cell Death Protein 1ImmunityInnate Immune ResponsePathway InteractionsPositioning AttributeFundingImmune Checkpoint InhibitorImmunotherapyInhibitorLeadMalignant NeoplasmsPhosphoric Diester HydrolaseDrug KineticsAdaptive Immune SystemFamily MemberCellsImmuneAdaptive Immune ResponseClinical TrialsCtla4 GeneCanis FamiliarisAdenosinePrograms
Grant awards (3)
A Phase 1-2 clinical program for the teatment of Microsatellite Stable Colorectal Cancer with the combination of SR-8541A, Botensilimab, and Balstilimab$1,460,952
R44 · FY2025 · CA · contact PI
Development of a potent and selective oral ENPP1 inhibitor for oncology$836,231
R44 · FY2023 · CA · contact PI
Development of a potent and selective oral ENPP1 inhibitor for oncology$1,160,011
R44 · FY2022 · CA · contact PI